Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study.
Recombinant human GH (hGH) combined with a permeation enhancer for the nasal mucosa, sodium tauro-24,25-dihydrofusidate (STDHF), was administered intranasally (in) in six patients with classical GH deficiency. Three different doses were tested (0.2, 0.4, and 0.8 IU/kg BW). The concentration of STDHF was 1% in all doses. As a comparison, all patients received a sc injection of hGH (0.1 IU/kg BW). Blood samples were obtained at frequent intervals for up to 8 h (in doses) or 24 h (sc dose) and analyzed for the plasma concentration of hGH. All three i.n. doses gave a rapid increase in hGH with peak maxima (Cmax) at 20-30 min, and a decline to baseline within 2-3 h. In contrast, the sc dose resulted in a Cmax 2-3 h after the injection, followed by a plateau phase for 2-3 h. The baseline was reached 12-14 h after administration. The uptake [area under the curve (AUC)] was considerably lower for all three in doses, i.e. 1.6-3% of the AUC obtained with the sc dose. However, the Cmax varied between 5.7 +/- 1.4% (0.8 IU/kg BW) and 15.8 +/- 2.1% (0.4 IU/kg BW) of the maximal peak with the sc dose. Of the in doses, 0.4 IU/kg BW resulted in the highest AUC and Cmax. A self-rating protocol was also used to estimate nasal sensations for up to 2 h after dosing. All sensations (itching, burning, sneezing, and running of the nose) were transient and tolerable. This study demonstrates that hGH can be administered intranasally in combination with STDHF. The in dosing results in a plasma peak of hGH very similar to the physiological endogenous peak. No side-effects were noted, other than a transient nasal irritation. Therefore, the nasal route for hGH administration offers a more physiological and more convenient alternative to injections for the treatment of GH deficiency.
Hedin
L
L
Department of Physiology, University of Goteborg, Sweden.
Olsson
B
B
Diczfalusy
M
M
Flyg
C
C
Petersson
A S
AS
Rosberg
S
S
Albertsson-Wikland
K
K
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D005672:Fusidic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D013006:Growth Hormone / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood* / Q000172:deficiency*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D009297:Nasal Mucosa / Q000187:drug effects; D011863:Radioimmunoassay
D004338:Drug Combinations; D005672:Fusidic Acid; C053824:tauro-24,25-dihydrofusidate; D013006:Growth Hormone